Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | GvHD in MM patients treated w/ dara post-alloHCT

Joshua Richter • 7 Jul 2020
General Multiple Myeloma Daratumumab

Joshua Richter, Mount Sinai Medical Center, New York, NY, discusses a multicenter retrospective study which evaluated the incidence of graft-versus-host disease (GvHD) in 34 patients with relapsed multiple myeloma treated with daratumumab after allogeneic hematopoietic cell transplantation (allo-HCT). Dr Richter and his colleagues concluded that the incidence of GvHD after daratumumab was low and did not result in increased exacerbation of GvHD in patients with a history of GvHD. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology.

More from Joshua Richter

1:33
Updates from the LINKER-MM1 study: linvoseltamab in R/R multiple myeloma
Joshua Richter • 27 Sep 2023
1:14
Prevention & monitoring of infections in patients with multiple myeloma treated with immunotherapies
Joshua Richter • 27 Sep 2023
1:44
Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma
Joshua Richter • 27 Sep 2023
1:45
The value of teclistamab in R/R myeloma & strategies to mitigate toxicities
Joshua Richter • 27 Sep 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals